Overview

Study of an Anti-TLR4 mAb in Rheumatoid Arthritis

Status:
Completed

Trial end date:
2018-06-20

Target enrollment:

Participant gender:

Summary

This is a Phase 2, PoC, randomized, placebo-controlled, double blind, international multicentre study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis

Phase:

Phase 2

Details

Lead Sponsor:

NovImmune SA

Treatments:

Antibodies
Antibodies, Monoclonal